ReNeuron Outlines First-To-Market Plans For Stroke Disability Cell Therapy
ReNeuron has high hopes of being the first to reach the US market with a novel stem cell therapy for use in patients with disabilities caused by stroke – CEO Olav Hellebø outlines the company's plans for Phase III and eventual commercialization.
You may also be interested in...
AZ’s MedImmune to use 4D’s AAV vector technology to deliver therapies for chronic lung disease, while Roivant spinout Dermavant licenses Phase III-ready autoimmune candidate tapinarof from GSK.
Encouraging early data from a Phase II trial of ReNeuron’s stem cell therapy CTX are adding to the evidence that it can improve patients with stroke disability, setting the stage for a pivotal trial next year.
Angeli Möller, recently spotlighted by In Vivo as a 2020 Rising Leader, has quickly moved up the ranks at Bayer and is now spearheading one of its key initiatives to bring artificial intelligence and machine learning technologies into the pharma business.